Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02979639 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 404
- Enrollment target
NCT02979639 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 404 participants.
The verdict
NCT02979639, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 404 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the impact of reactogenicity of GSK Biologicals' HZ/su vaccine on Quality of Life (QoL) in adults ≥ 50 years of age
Interventions
- BIOLOGICAL GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2017-01-16 |
| Est. Completion | 2018-05-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02979639
The ClinicalTrials.gov registry entry for NCT02979639 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 404 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) is the first listed.
NCT02979639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02979639 about?
NCT02979639 is a clinical study titled "Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age". The purpose of this study is to evaluate the impact of reactogenicity of GSK Biologicals' HZ/su vaccine on Quality of Life (QoL) in adults ≥ 50 years of age
What is the current status of trial NCT02979639?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 404 participants. The study started on 2017-01-16. Estimated completion is 2018-05-24.
What interventions are being tested in trial NCT02979639?
The interventions under investigation include: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02979639?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.